Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis-MedSci.cn

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Mathur, VS; Bushinsky, DA; Inker, L; Klaerner, G; Li, E; Parsell, D; Perkovic, V; Stasiv, Y; Walker, M; Wesson, DE; Wheeler, DC; Tangri, N

Tangri, N (通讯作者)，Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Internal Med, Winnipeg, MB, Canada.

Abstract

Background Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established. Veverimer is a novel hydroc......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

科室

工具

服务